Using AI tools can ‘deskill' certain health workers
Academics said that the finding is 'concerning' given the rapid uptake of artificial intelligence (AI) across healthcare.
The new study looked at health workers who perform a test to look for early signs of bowel cancer.
Endoscopists perform a test called a colonoscopy to look for precancerous growths in the bowel known as adenomas.
This means these pre-cancerous growths can be detected and removed, preventing them from becoming bowel cancer.
Advances in AI technology have led to the development of computer-assisted polyp detection systems, which have been found to help these health workers spot more adenomas.
Researchers wanted to assess whether continuous use of AI led to a dip in performance when endoscopist perform colonoscopies without AI by analysing work conducted in Poland.
The research team analysed 1,442 colonoscopies conducted by experienced health workers before and after AI systems were rolled out at certain centres in 2021.
Writing in the journal Lancet Gastroenterology and Hepatology, researchers reported that the rate of detection of polyps was 6% lower after the introduction of AI in standard and non-AI assisted colonoscopies.
'To our knowledge this is the first study to suggest a negative impact of regular AI use on healthcare professionals' ability to complete a patient-relevant task in medicine of any kind,' said one of the study authors, Dr Marcin Romanczyk, Academy of Silesia in Poland.
'Our results are concerning given the adoption of AI in medicine is rapidly spreading.
'We urgently need more research into the impact of AI on health professional's skills across different medical fields.
We need to find out which factors may cause or contribute to problems when healthcare professionals and AI systems don't work well together, and to develop ways to fix or improve these interactions.'
In a linked editorial, Omer Ahmad, a consultant gastroenterologist and interventional endoscopist and clinical research fellow at University College London, wrote: 'These findings temper the current enthusiasm for rapid adoption of AI-based technologies such as CADe and highlight the importance of carefully considering possible unintended clinical consequences.
'The study provides the first real-world clinical evidence for the phenomenon of deskilling, potentially affecting patient-related outcomes.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
43 minutes ago
- Telegraph
NHS to pilot AI prostate cancer tests
An AI tool to spot prostate cancer earlier is being piloted by the NHS. The two-year scheme involving more than 3,000 men aims to speed up diagnosis of the disease, which is the most common form of cancer in men. Every year around 55,000 men in the UK are diagnosed with prostate cancer and 12,000 die from it. But just half of cases are caught at an early stage, when treatment is most effective. Trials suggest the technology can help radiologists detect around 11 per cent more early-stage cancers by highlighting suspicious regions in MRI scans. The software by Quibim uses advanced AI, trained on real pathology results, to segment the prostate into zones and highlight areas most likely to contain aggressive disease. The two-year pilot, backed by £2.6 million in NHS funding, will be rolled out to seven hospitals in England. Clinical trials suggest it can raise detection rates from 80 per cent to more than 90 per cent. Early detection dramatically improves survival rates. Almost all men who are diagnosed with stage one or two of the disease are alive five years later, compared with rates of less than 50 per cent for those with late-stage disease. As well as looking at detection rates, the pilot will examine the cost-effectiveness of the approach to see if the NHS can save money by catching the disease sooner. It will also examine the impact on inequalities in heath, with black men twice as likely to get prostate cancer. Prof Peter Johnson, national clinical director for cancer at NHS England, said: 'The NHS is funding and testing this exciting AI technology to help us diagnose and treat prostate cancer patients as quickly as possible and offer them the best chance of survival. 'As part of the 10-Year Health Plan, the NHS is taking advantage of our unique position to test state-of-the-art technology like this, and rolling it out as fast as we can to make the NHS fit for the future.' Dr. Ángel Alberich-Bayarri, chief executive of Quibim said: 'This NHS rollout is a major milestone in our mission to improve cancer diagnostics through AI. 'We're proud to support the NHS in advancing early detection and addressing health inequalities in prostate cancer care. By empowering radiologists with AI, we can help ensure more men are diagnosed earlier, when their chances of survival are highest.' Screening could cut deaths by 40 per cent The findings come as The Telegraph launches a campaign calling for the introduction of targeted screening for prostate cancer. Currently, men are not offered tests, even if they have a family history of the disease. Experts believe there is a growing case for targeted screening, meaning that PSA blood tests would be offered to those at heightened risk of the disease. Even though prostate cancer is the most-common male cancer in the UK, it is the only major cancer with no screening programme. The UK National Screening Committee (UKNSC) is currently considering whether to recommend the rollout of testing. In the past, it has rejected the idea because of concern that PSA tests are too unreliable, and would result in too many men undergoing needless procedures. In recent years, however, the back-up technology used to confirm a diagnosis has significantly improved, with hopes that further advances being tested, could mean that in the future, screening could cut deaths by 40 per cent. Prof Shonit Punwani, Professor of magnetic resonance and cancer imaging and consultant radiologist at UCLH, said: 'Initial studies have shown that the tool helps radiologists to enhance their diagnostic accuracy through identifying subtle early stage lesions that are sometimes not obvious on scans. 'Ultimately, QP-Prostate aims to improve patient outcomes by assisting radiologists in creating more accurate and reliable MRI reports.'
Medical News Today
10 hours ago
- Medical News Today
Zilbrysq (zilucoplan) and cost
The cost of Zilbrysq can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you'll pay for cost and savingsAs with all medications, the cost of Zilbrysq can vary. Factors that may affect the price for Zilbrysq you'll pay include:your treatment planyour insurance coveragethe pharmacy you usethe cost of the visit to your healthcare professional to receive your first doses of Zilbrysqwhether Zilbrysq has a savings program (see the 'Financial and insurance assistance' section)To find out what the cost of Zilbrysq will be for you, talk with your doctor, pharmacist, or insurance vs. genericZilbrysq is only available as a brand-name drug. It doesn't come in a generic version. A generic drug is an exact copy of the active ingredient in a brand-name tend to cost less than brand-name ARE COSTS DIFFERENT FOR BRAND-NAME DRUGS VS. GENERIC DRUGS?Brand-name drugs can be expensive because of the research needed to test their safety and effectiveness. The manufacturer of a brand-name drug can sell it for up to 20 years. When the brand-name drug's patent expires, multiple manufacturers can create generic versions. This marketplace competition may lead to lower costs for generics. Also, because generics contain the same active ingredients as brand-name drugs, they don't require the same costly to reduce long-term drug costsIf you take Zilbrysq long term, you may be able to lower its cost in the following a 3-month supplyYou may be able to get a 90-day supply of Zilbrysq. If approved by your insurance company, getting a 90-day supply of the drug could reduce your number of trips to the pharmacy and help lower the cost. If you're interested in this option, check with your doctor, pharmacist, or insurance and insurance assistanceIf you need financial support to pay for Zilbrysq, or if you need help understanding your insurance coverage, help is available. For example:A program called ONWARD is available for Zilbrysq. For more information and to find out whether you're eligible for support, call 844-669-2731 or visit the program websites provide details about drug assistance programs, ways to make the most of your insurance coverage, and links to savings cards and other services. Two such websites are: Medicine Assistance ToolNeedyMeds» Learn more about saving money on prescriptions with or without considerationsYou may want to consider the following information if you have insurance and receive you have insurance, your insurance company may require prior authorization before it covers Zilbrysq. This means the company and your doctor will discuss Zilbrysq in regard to your treatment. The insurance company will then determine whether the medication is a drug requires prior authorization but you start treatment without the prior approval, you could pay the full cost of the medication. You can ask your insurance company whether Zilbrysq requires prior Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
The Independent
12 hours ago
- The Independent
You can now give yourself an at-home flu vaccine
For the first time, Americans can get their seasonal flu vaccine at home. Starting Friday, eligible adults in 34 states can order the FluMist Home - a nasal spray - online ahead of the upcoming flu season, European drugmaker AstraZeneca announced, calling it a 'transformational moment in the evolution of influenza protection.' FluMist was previously only available at pharmacies or doctors' offices. Now, interested people can go to to order the sprays, potentially saving time spent at a clinic or drug store. Once received, the vaccine should be stored in the refrigerator until it is used. Then, people between the ages of 18 and 49 years old can self-administer the vaccine. FluMist Home can be given to children and teens between the ages of two and 17 years old. A full dose is one spray in each nostril. FluMist may not prevent infection in everyone who takes it, but it works similarly to vaccines for measles and chickenpox. It contains weakened versions of viruses that trigger the immune system in the nose and throat, teaching it to build up immunity without causing infection. In rare cases, FluMist may cause serious side effects, including allergic reactions. But the most common side effects are a runny or stuffy nose, a sore throat and a fever of over 100 degrees. Some people should not take FluMist, including those with severe allergies to eggs, the vaccine's ingredients, or other flu vaccines, and kids who take aspirin or medicines containing aspirin. Children should also not take aspirin for four weeks after they get FluMist, unless told to do so by a healthcare provider. The spray, which was initially approved by the Food and Drug Administration in 2003 and was approved for at-home use without a healthcare professional last September, should be free for people with insurance, though there is an $8.99 shipping and processing fee. AstraZeneca said it hopes that all of the lower 48 states will have access to the spray in future flu seasons, although when that may be is unclear. The announcement comes on the heels of the worst flu season in 15 years, fueled by a cold winter, the spread of H5N1 bird flu, Covid, and other respiratory illnesses, and declining vaccine rates. Falling vaccination was 'a major cause of the surge,' Dr. Elizabeth Mack, the head of the pediatric critical care unit at the Medical University of South Carolina's Children's Health, told National Geographic. 'As influenza vaccination rates decline, especially among younger populations, this first-of-its-kind, at-home, needle-free option offers a critical opportunity to help make protection more accessible, convenient, and better aligned with the realities and current preferences of people's lives,' Dr. Ravi Jhaveri, the division head of infectious diseases at Northwestern University School of Medicine, said of FluMist Home, in a statement shared by AstraZeneca.
